{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011868","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.841205+00:00","generated_at":"2026-06-13T08:33:45.010595+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Protalix BioTherapeutics shareholders approve increase in authorized common shares from 144M to 185M","bullets":["Amendment to Certificate of Incorporation approved at reconvened 2023 Annual Meeting on July 13, 2023.","Authorized common shares increased by 41M, from 144M to 185M.","Votes: 33,870,055 for, 9,479,063 against, 1,042,433 abstentions.","Proposal passed with approximately 76% of votes cast in favor."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011868","json":"https://secwatch.observer/filing/0001558370-23-011868.json","markdown":"https://secwatch.observer/filing/0001558370-23-011868.md","text":"https://secwatch.observer/filing/0001558370-23-011868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011868/0001558370-23-011868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011868/plx-20230713x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:33:45.010595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}